Autosomal dominant hypercholesterolemia (ADH), more known as familial hypercholesterolemia (FH), is a lipid metabolism disorder characterized by an elevation in low-density lipoprotein cholesterol (LDL-C) and increased risk for cardiovascular disease.
Introduction
Autosomal dominant hypercholesterolemia (ADH), more known as familial hypercholesterolemia (FH), is a lipid metabolism disorder that results in both total and low-density lipoprotein cholesterol (LDLc) elevation and increased risk for cardiovascular disease. Pathogenic variants in the three genes -LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein covertase subtilisin/kexin type 9 (PCSK9) have been established as causatives of the disease (Chiou and Charng 2010) . Recently, mutations in signal transducing adaptor family member 1 gene (STAP1) (Fouchier et al. 2014) and several other genes (Santos et al. 2016) were described in association with ADH. Recent studies in unselected general populations suggest that the prevalence of heterozygous autosomal dominant hypercholesterolemia may be as high as 1 in 200 (Nordestgaard et al. 2013 , Sjouke et al. 2015 . Consequently, homozygous autosomal dominant hypercholesterolemia may affect as many as 1 in 160,000-300,000 people (Cuchel et al. 2014) .
In 1998, the MedPed (Make Early Diagnosis for prevent Early Deaths in medical pedigrees; http://www.medped.org/) project was established in the Czech Republic. This international humanitarian nonprofit project was founded in the USA. The goal of this project is to prevent premature deaths from ischemic cardiovascular S48 Tichý et al. Vol. 66 events by finding high risk individuals with ADH who are either undiagnosed or inadequately treated and by consequent identification of their affected relatives.
Development of molecular diagnostics
Our cohort of unrelated patients referred to molecular diagnostics included 1) patients with untreated total and/or LDL cholesterol serum levels above the 95th percentile of age, sex and population-specific values (Cífková R, personal communication, Šamánek et al. 1997) ; 2) patients with elevated total and/or LDL cholesterol in serum but untreated levels unavailable or not exceeding the 95th percentile of age, sex and population-specific values, and, in addition, having high clinical suspicion of ADH based on personal history and/or family history of premature coronary heart disease and/or elevated total and LDL cholesterol serum levels in first degree relatives.
In the Czech Republic, ADH molecular diagnostics started in 1997. Large scale of methods has been used for analysis since that time. The first diagnostics scheme for LDLR gene analysis was based on the amplification of all LDLR gene exons and intronic junctions and their analysis by denaturing gradient gel electrophoresis (DGGE). In cases of positive results, direct sequencing was performed in these samples.
In 2002, we published the first spectrum of mutations in Czech hypercholesterolemic patients (Kuhrova et al. 2002) . There was evidence of some mutations being more prevalent in our population. Due to this fact, we changed the diagnostics scheme in 2002 and introduced denaturing high performance liquid chromatography (dHPLC) to rapidly screen for mutations in the LDLR gene. DNA analysis of ADH patients was divided into several consecutive steps: 1) PCR-RFLP (Restriction Fragment Length Polymorphism) detection of the most common mutation in the APOB gene 3) PCR-sequencing of LDLR exon 4 (the exon with the markedly most frequent occurrence of mutations in our patients); 4) PCR-sequencing of the promoter and LDLR exons 1, 5, 6, 9, 10, 12, 14; and 5) PCR-dHPLC of LDLR exons 2, 3, 7, 8,11, 13, 15, 16, 17, and 18 , followed by sequencing of regions which were tested positive. In 2005, we added multiplex ligation-dependent probe amplification (MLPA). In mutation detection, further DNA analysis continued when 1) a phenotypic manifestation was serious and possibly associated with the presence of two ADH mutations or 2) a detected mutation was new with an effect on the protein structure and function, which was difficult to predict. This diagnostic process was common in ADH/FH molecular genetic testing worldwide in that time (Civiera et al. 2008) .
In 2010, we introduced high throughput Arrayed Primer Extension (APEX)-based genotyping DNA microarray (Dušková et al. 2011) . In populations such as Ashkenazi (Meiner et al. 1991) and Sephardic Jews (Leitersdorf et al 1993) , Icelanders (Gudnason et al. 1997 ), or Finns (Koivisto et al. 1995 , a few mutations predominate due to founder effects. On the contrary, we found over 180 types of mutations in the LDLR gene in Czech patients and on average, 6 novel types of ADH mutations are found per year. We concluded that APEX-based genotyping DNA microarray is not suitable for routine use in diagnostics in our population. Complete direct sequencing of whole coding sequence of LDLR gene in all samples was performed from 2012 to 2014.
The current diagnostic scheme was initiated in 2014 and is based on next generation sequencing for all exons (and adjacent intronic junctions) of the LDLR and the PCSK9 genes, partial sequencing of the APOB gene (part of exon 26 from c.10200 to c.11100) and analysis of 12 functional polymorphisms in other genes (Talmud et al. 2013) . We use ADH Master kit manufactured by Multiplicom, Niel, Belgium. In negative samples, LDLR gene MLPA is performed as the second step of the standard diagnostic scheme.
Results and milestones
The group of 3914 unrelated patients diagnosed with ADH, submitted to the database of the MedPed project in the Czech Republic, has been analyzed for the presence of mutations in the APOB and LDLR genes since 1997. Analysis of the PCSK9 gene was completed in 533 patients. We confirmed the FH diagnosis in 1296 patients (33.11 %) -432 patients carrying a mutation in the APOB gene and 864 patients in the LDLR gene. No ADH causing gain-of-function mutation in the PCSK9 gene was found in this study group of patients. These results are comparable with published studies from other European countries (Chmara et al. 2010 , Widhalm et al. 2007 , Grenkowitz et al. 2016 , Kindt et al. 2013 , Gabčová et al. 2017 , Nauck et al. 2001 . It is notable that the most frequent mutation in Czech ADH patients p.(Gly592Glu) is also the most common in Slovakia (Gabčová et al. 2017 ) and in Poland (Chmara et al. 2010) , the second most common mutation p.(Asp266Glu) is the most common in Germany (Nauck et al. 2001) and Austria (Widhalm et al. 2007 ) and the third most common mutation p.(Arg416Trp) is also very frequent in Slovakia. In probands carrying an LDLR gene mutation, 182 unique allelic variants were detected: 72.8 % of these variants were DNA substitutions, 15.8 % of small DNA rearrangements, and (of before each of the percentages or none) of 11.4 % large DNA rearrangements. Detailed differentiation of the so far detected variants is shown in Figure 1 . In the Czech MedPed project database there are actually 6929 patients clinically diagnosed with ADH. Preliminary data suggest a polygenic base of ADH in part of this cohort (Fellnerová et al. 2014 , Schwarzova et al. 2016 . In comparison with published data (Nordestgaard et al. 2013) , the Czech Republic has the third highest proportion of clinically diagnosed patients from all assessed countries (Fig. 2) . We found 14 patients homozygous for mutation in causative genes -10 patients carry mutations in the LDLR gene (7 of them are compound heterozygotes, while 3 remaining are true homozygotes) and 3 patients are carriers of the p.(Asp3527Gln) mutation in both APOB gene alleles. 
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In 2004, we published our first functional assay for a mutation found in Czech patients (Francová et al. 2004) . The described mutation c.-120C>T is located between the TATA box and the sterol-dependent regulatory element repeat 3. Using a luciferase reporter assay system, we analyzed the transcriptional efficiency of the normal and mutant alleles. The mutation reduced promoter activity to a background level. The next three promoter mutations found in Czech patients (c.-153C>T, c.-149C>A and c.-140C>A) are located in the sterol regulatory element (SRE) or the SP1 site. The analyses sequence variation impact in these regulation sites revealed an 80-95 % decrease in activity compared with a wild type promoter (Südhof et al. 1987) .
In 2005, we introduced the MLPA reaction into a diagnostic scheme. During the following five years we found 8 different types of large rearrangements, among these 6 were of novel types, not described so far. In all these rearrangements, we characterized their exact extent and breakpoint sequences (Goldmann et al. 2010) . The results showed that 6 events were products of NAHR (non-allelic homologous recombination) between Alu repeat sequences. The remaining 2 events apparently originated from NHEJ (non-homologous end joining). While NAHR was described in relation to the LDLR gene earlier, our study was the first describing NHEJ in LDLR genomic rearrangements. Actually, duplication including exons 2-6 is the fifth most common mutation in Czech ADH patients.
In 2012, we published an actual list of mutations found in ADH patients in the Czech Republic up to date (Tichý et al. 2012) . The large set of clinical information in the Czech MedPed database allowed us to perform detailed phenotype-genotype correlation in our ADH patients. For lipid profile analyses, ADH probands were divided into 3 groups: i) patients with the LDLR mutation (LDLR+), ii) with the APOB p.(Arg3527Gln) mutation (APOB+) and iii) without a detected mutation (LDLR-/ APOB-). Each group was divided into subgroups according to gender. Significant gradients in i) total cholesterol (LDLR+ patients > APOB+ patients = LDLR-/ APOB-patients), ii) LDL cholesterol (LDLR+ patients >APOB+ patients = LDLR-/APOB-patients in men and LDLR+ patients > APOB+ patients > LDLR-/APOBpatients in women), iii) triglycerides (LDLR-/APOBpatients > LDLR+ patients > APOB+ patients), and iv) HDL cholesterol (APOB+ patients > LDLR-/ APOB-patients = LDLR+ patients) were shown. The occurrence of cardiovascular events and tendon xanthomas was 16.4 % and 3.8 % respectively, in the set of our ADH patients older than 30 years of age. The highest incidence of these clinical features was recorded in the LDLR+ group (20.8 % and 13.1 %), in which the highest LDL cholesterol level was also demonstrated (Tichý et al. 2012) .
Here we present the list of point mutations, small deletions/insertions (Table 1 ) and large rearrangements (Table 2) found in our patients, which were not included in our previous publications. Pathogenic impact on the LDL receptor protein structure and function was predicted by in silico approaches (PolyPhen2, SIFT and Mutation Taster). We use aggregated data from ExAC (http://exac.broadinstitute.org/) and 1000 Genomes (http://browser.1000genomes.org) databases for evaluation of sequence variants frequencies in random population.
Most recently, we published our results from the function analysis of controversial sequence variant c.58G>A (p. (Gly20Arg) (Gly20Arg) is able to reach the cell membrane and to bind the LDL particle in a similar way as the wt LDLR protein. We assume that the binding activity of the mutated protein is not affected because p.(Gly20Arg) is localized in signal peptide, which is cleaved in endoplasmic reticulum and is not present in mature protein. Currently, we continue with these analyses in other mutations. (Schwarz et al. 2014) , were used to predict the effect of missense mutations or small deletion/insertion on the LDLR protein. Although helpful, it should be remembered that these computer prediction programs provide only an indication that an amino acid substitution may affect the biological activity of the mature protein. Table 2 . List of large rearrangements found in the LDLR gene, which were not published in our previous study (Tichý et al. 2012 ). Sequence events long than 100 bp are considered as large duplication/insertion/deletion.
No. Deletion/Duplication Number of proband
Ex13_14del 2
In conclusion, the molecular diagnostic of ADH in the Czech Republic is well organized especially due to the MedPed project. The results achieved in the number of diagnosed patients as well as in the field of translation medicine are comparable with other countries worldwide.
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